SlideShare a Scribd company logo
1 of 13
The Prevalence Of Retinopathy Of
Prematurity And Relationship With Various
Factors Among Infants Admitted In SNCU
,RIMS RANCHI Contributing To Screening
Programmes
By - Dr. Abhishek Kumar
Sinha
Junior Resident,R.I.M.S
Ranchi
Introduction
❖ Retinopathy of prematurity (ROP) is a proliferative retinopathy which is the preventable
common cause of the blindness in preterm infants. Detection and treatment of the ROP have
become more important because the progression of the disease is very quick. It has several
risk factors but the most important risk factors are low gestational age (GA) and low birth
weight (BW) [1]. A lot of screening guidelines have been based on these factors to identify
infants needing examination.
❖ The incidence of the ROP is different in countries. In developed countries, ROP-associated
blindness incidence has been reported to be lower than 10% of extremely preterm born
children but in middle-income countries, the incidence is greater than 40% .
❖ In this retrospective study, we analyzed the incidence of ROP. We aimed to contribute to
screening programmes.
Subjects and Methods
❖ Approval was obtained from the local ethics committee for the study. The
study conformed to the tenets of the Declaration of Helsinki.
❖ In this retrospective study,182 premature infants who were born with GA ≤ 37
weeks at our hospital were examined.
❖ Exclusion criteria were lethal congenital anomalies, death before examination,
death or loss to follow up before complete retinal vascularisation has
developed and incomplete screening procedure.
❖ ROP was classified according to the international classification of ROP
and screening procedure was designed in accordance with suggestions of
the American Academy of Pediatrics, American Academy of
Ophthalmology and American Association for Pediatric Ophthalmology
and Strabismus.
❖ The diagnosis of severe ROP is defined as threshold and type 1 pre-
threshold ROP. The Early Treatment for Retinopathy of Prematurity
(ETROP) study results recommended treating ROP with laser
photocoagulation. In zone II or III cases, we preferred laser treatment. In
zone I or posterior zone II cases, we prefer anti-VEGF.
❖ Infants were classified into 4 groups according to GA; < 28 week, 28 - 31
weeks, 32 - 34 weeks, 35 - 37 weeks. Infants also classified into 8 groups
according to the BW; ≤ 750g, 751 - 999g, 1000 - 1249g, 1250 - 1499g, 1500 -
1749g, 1750 - 1999g, 2000 - 2499g, ≥ 2500g.
❖ Data analysis was conducted using SPSS V.20.0 (SPSS Inc., Chicago, IL).
Chi-square test was used to analyze qualitative variables. A difference with p
< 0.05 was considered significant.
Results
❖ During the study period, a total number of 182 preterm infants [105 female
(58%) & 77 male (42%)] with ≤ 37 week of GA were assessed. Mean GA was
31.9 ± 2.1 weeks (range: 25 - 37 weeks) and mean BW was 1575.4 ± 495.2g
(range: 690 - 4050g).
❖ The overall incidence of ROP was 35% (63/182). 36 infants (58%) had stage 1,
7 infants (10%) had stage 2, 14 infants (22%) had stage 3, 2 infants (0.03%) had
stage 4 and 5 of the disease and 4 infants (0.07%) had aggressive posterior
retinopathy of prematurity (APROP). Mean GA who had any stage of the
disease was 30.1 ± 2.1 weeks (range: 24 - 35.9 weeks) and mean BW was
1263.6 ± 390.2g (range: 690 - 3190g).
❖ The incidence of ROP in female and male infants were 39% (40/105), 29%
(22/77), respectively. There was no significant difference between genders
(p = 0.065).
❖ The incidence of ROP in GA with < 28 week was 100%, 28 - 31 weeks was
63%, 32 - 34 weeks was 15%, 35 - 37 weeks was 13%. The incidence rate of
the disease was increased with the decrease in the GA (p < 0.001)
Variables
ROP
Number(%)
No ROP
Number (%)
P
Gender
Female
Male
40(39%)
22(29%)
64(61%)
55(71%)
0.065
Gestational age
(weeks)
< 28 weeks
28 - 31 weeks
32 - 34 weeks
35 - 37 weeks
10(100%)
36(63%)
11(15%)
5(13%)
0(0%)
21(37%)
67(85%)
32(87%)
<0.001
Birth weight (g)
< 750 g
750 - 999g
1000 - 1249g
1250 - 1499g
1500 - 1749g
1750 - 1999g
2000 - 2499g
> 2500g
1(100%)
10(91)
10(71%)
11(44%)
13(37%)
9(29%)
4(11%)
5(16%)
0(0)
1(9%)
5(29%)
13(56%)
23(63%)
22(71%)
33(89%)
22(84%)
<0.001
Variables
Stage 1 Stage 2 Stage 3 Stage 4a Stage 4b Stage 5 APROP P
Gender
Female
Male
22(56%)
12(62%)
5(12%)
2(9%)
9(22%)
5(21%)
1(2%)
0(0%)
0(0%)
1(0.5%)
0(0%)
0(0%)
3(8%)
2(1%)
0.940
Gestational age
(weeks)
< 28 weeks
28 - 31 weeks
32 - 34 weeks
35 - 37 weeks
3(30%)
21(58%)
7(69%)
3(60%)
2(20%)
4(11%)
0(0%)
1(20%)
3(30%)
7(20%)
3(23%)
1(20%)
0(0%)
1(3%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
2(20%)
3(8%)
1(8%)
0(0%)
0.018
Birth weight (g)
< 750 g
750 - 999g
1000 - 1249g
1250 - 1499g
1500 - 1749g
1750 - 1999g
2000 - 2499g
> 2500g
0(0%)
4(40%)
5(50%)
6(63)
5(54%)
10(76%)
2(67%)
2(50%)
0(0%)
1(1%)
2(20)
4(13%)
0(0%)
0(0%)
0(0%)
1(25%)
2(67%)
3(30%)
2(20)
2(21%)
0(0%)
0(0%)
1(33%)
1(25%)
0(0%)
1(10%)
0(0%)
0(0%)
4(36%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
1(33%)
1(10%)
2(20%)
1(4%)
1(11%)
3(24%)
0(0%)
0(0%)
0.038
Discussion
❖ ROP is a preventable blinding disease of the retina. Although diagnosing and
treatment methods have been developed, ROP still threat premature infants
all over the world especially in middle-income countries such as India,
China,other parts of Asia, Eastern Europa, Latin America. Detection and
treatment with the screening programs are very important to prevent poor
vision. For screening programmes, detection of the risk factors and incidence
of ROP are essential. There are several risk factors in the development of
ROP but the BW and GA are considered the most important risk factors of
the disease
The Prevalence of Retinopathy of Prematurity and Relationship with Gestational
Age and Birth-Weight; Contributing to Screening Programmes
❖ In our study, the overall incidence of ROP was 35% and incidence of any stage of
ROP was 100% of infants with GA less than or equal to 28 weeks and 63% with GA
less than or equal to 32 weeks. We also found that the incidence of ROP BW with <
750g was 100%, 750 - 999g was 91%, 1000 - 1249g was 71% and 1250 - 1499g was
44%.
❖ In our country, our city &. nearby areas are less developed-region and socioeconomic
status of the population is low and these situations can explain the reason for high
incidence. The other reasons may be low prenatal care, delivery care, and postnatal
care standards.
❖ Screening criteria usually base on gestational age and birth weight. Several studies
have been done to create criteria for ROP screening programmes. These programmes
differ from one country to another country and change from time to time.
Limitation
❖ This study has some limitations. First of all, the study population is small &
the study was conducted in Ranchi only, so the results may not reflect the
true incidence of ROP in India.
Conclusions
❖ ROP is still a serious disease and its incidence is different between countries
and change from time to time according to the neonatal healthcare units
conditions and their developments.
❖ Screening criteria for ROP in our country must be wider than high-income
countries. In India, neonatal healthcare unit conditions should be improved
and national guidelines for ROP should be established.

More Related Content

What's hot

Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
Anisha Rathod
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
Paavan Kalra
 

What's hot (20)

ROP current understanding and management
ROP current understanding and managementROP current understanding and management
ROP current understanding and management
 
Retinopathy of prematurity rop satish 1
Retinopathy of prematurity rop satish 1Retinopathy of prematurity rop satish 1
Retinopathy of prematurity rop satish 1
 
seminar on ROP - retinopathy of prematurity
seminar on ROP - retinopathy of prematurityseminar on ROP - retinopathy of prematurity
seminar on ROP - retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Rop seminar
Rop seminarRop seminar
Rop seminar
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity by dr sonali paradhi mhatre
Retinopathy of prematurity  by dr sonali paradhi mhatreRetinopathy of prematurity  by dr sonali paradhi mhatre
Retinopathy of prematurity by dr sonali paradhi mhatre
 
Rop – emerging therapies march 2011
Rop – emerging therapies march 2011Rop – emerging therapies march 2011
Rop – emerging therapies march 2011
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity 2014 july 11
Retinopathy of prematurity 2014 july 11Retinopathy of prematurity 2014 july 11
Retinopathy of prematurity 2014 july 11
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity, Therapy Modalities, BIUMS, Dr Joobin Khadamy, 1st...
Retinopathy of prematurity, Therapy Modalities, BIUMS, Dr Joobin Khadamy, 1st...Retinopathy of prematurity, Therapy Modalities, BIUMS, Dr Joobin Khadamy, 1st...
Retinopathy of prematurity, Therapy Modalities, BIUMS, Dr Joobin Khadamy, 1st...
 
retinopathy of prematurity
retinopathy of prematurityretinopathy of prematurity
retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
retinopathy of prematurity
retinopathy of prematurityretinopathy of prematurity
retinopathy of prematurity
 
Retinopathy of prematurity
Retinopathy of prematurityRetinopathy of prematurity
Retinopathy of prematurity
 
Steroids in neonatology Steroids in neonatology
Steroids in neonatology  Steroids in neonatology Steroids in neonatology  Steroids in neonatology
Steroids in neonatology Steroids in neonatology
 
Journal reading: Intravitreal bevacizumab for ROP : refractive error results
Journal reading: Intravitreal bevacizumab for ROP : refractive error resultsJournal reading: Intravitreal bevacizumab for ROP : refractive error results
Journal reading: Intravitreal bevacizumab for ROP : refractive error results
 

Similar to Prevalence of Retinopathy of Prematurity

Low birthweight delivery prevalence and associated factors as seen at a terti...
Low birthweight delivery prevalence and associated factors as seen at a terti...Low birthweight delivery prevalence and associated factors as seen at a terti...
Low birthweight delivery prevalence and associated factors as seen at a terti...
Michael Olafusi
 
Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...
Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...
Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...
International Multispeciality Journal of Health
 

Similar to Prevalence of Retinopathy of Prematurity (20)

IUGR.pptx
IUGR.pptxIUGR.pptx
IUGR.pptx
 
Sub1591
Sub1591Sub1591
Sub1591
 
I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad
 
Placental Elastography in Intrauterine Growth Restriction: A Case–control Study
Placental Elastography in Intrauterine Growth Restriction: A Case–control StudyPlacental Elastography in Intrauterine Growth Restriction: A Case–control Study
Placental Elastography in Intrauterine Growth Restriction: A Case–control Study
 
Iugr vld
Iugr vldIugr vld
Iugr vld
 
screening for down syndrome
screening for down syndromescreening for down syndrome
screening for down syndrome
 
Screening what tests when
Screening what tests whenScreening what tests when
Screening what tests when
 
Update on retinopathy of prematurity
Update on retinopathy of prematurityUpdate on retinopathy of prematurity
Update on retinopathy of prematurity
 
final ROP seminar (1).pptx
final ROP seminar (1).pptxfinal ROP seminar (1).pptx
final ROP seminar (1).pptx
 
Retinopathy of prematurity by dr. tareq rahman
Retinopathy of prematurity by dr. tareq rahmanRetinopathy of prematurity by dr. tareq rahman
Retinopathy of prematurity by dr. tareq rahman
 
Low birthweight delivery prevalence and associated factors as seen at a terti...
Low birthweight delivery prevalence and associated factors as seen at a terti...Low birthweight delivery prevalence and associated factors as seen at a terti...
Low birthweight delivery prevalence and associated factors as seen at a terti...
 
Normal and abnormal delivery Dr Falakha
Normal and abnormal delivery Dr FalakhaNormal and abnormal delivery Dr Falakha
Normal and abnormal delivery Dr Falakha
 
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCEF.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
F.G.R. PANEL DISCUSSION AT FOGSI BOH CONFERENCE
 
Interesting Update on Recurrent Miscarriage for Indian Gynaecologoists D...
Interesting Update on  Recurrent  Miscarriage  for Indian Gynaecologoists   D...Interesting Update on  Recurrent  Miscarriage  for Indian Gynaecologoists   D...
Interesting Update on Recurrent Miscarriage for Indian Gynaecologoists D...
 
Neonatal and Obstetric Risk Assessment (NORA) Pregnancy Cohort Study in Singa...
Neonatal and Obstetric Risk Assessment (NORA) Pregnancy Cohort Study in Singa...Neonatal and Obstetric Risk Assessment (NORA) Pregnancy Cohort Study in Singa...
Neonatal and Obstetric Risk Assessment (NORA) Pregnancy Cohort Study in Singa...
 
Neurodevelopmental follow up
Neurodevelopmental follow upNeurodevelopmental follow up
Neurodevelopmental follow up
 
Jc aprile 2017
Jc aprile 2017Jc aprile 2017
Jc aprile 2017
 
Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...
Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...
Pregnancy Outcomes of Oligohydramnios at Term diagnosed by Ultra Sonography (...
 
Management of IVF Pregnancy
Management of IVF PregnancyManagement of IVF Pregnancy
Management of IVF Pregnancy
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
 

Recently uploaded

CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancementsCAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
Naveen Gokul Dr
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Abortion pills in Kuwait Cytotec pills in Kuwait
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
MedicoseAcademics
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
JRRolfNeuqelet
 

Recently uploaded (20)

Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...
Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...
Young & Hot ℂall Girls Salem 8250077686 WhatsApp Number Best Rates of Surat ℂ...
 
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancementsCAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
CAD CAM DENTURES IN PROSTHODONTICS : Dental advancements
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
duus neurology.pdf anatomy. phisiology///
duus neurology.pdf anatomy. phisiology///duus neurology.pdf anatomy. phisiology///
duus neurology.pdf anatomy. phisiology///
 
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
Best medicine 100% Effective&Safe Mifepristion ௵+918133066128௹Abortion pills ...
 
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
 
Young & Hot ℂall Girls Patna 8250077686 WhatsApp Number Best Rates of Patna ℂ...
Young & Hot ℂall Girls Patna 8250077686 WhatsApp Number Best Rates of Patna ℂ...Young & Hot ℂall Girls Patna 8250077686 WhatsApp Number Best Rates of Patna ℂ...
Young & Hot ℂall Girls Patna 8250077686 WhatsApp Number Best Rates of Patna ℂ...
 
Vesu + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7 C...
Vesu + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7 C...Vesu + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7 C...
Vesu + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7 C...
 
Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...
Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...
Kamrej + ℂall Girls Serviℂe Surat (Adult Only) 8849756361 Esℂort Serviℂe 24x7...
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
VIP ℂall Girls Kandivali west Mumbai 8250077686 WhatsApp: Me All Time Serviℂe...
VIP ℂall Girls Kandivali west Mumbai 8250077686 WhatsApp: Me All Time Serviℂe...VIP ℂall Girls Kandivali west Mumbai 8250077686 WhatsApp: Me All Time Serviℂe...
VIP ℂall Girls Kandivali west Mumbai 8250077686 WhatsApp: Me All Time Serviℂe...
 
Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?
 
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessSigns It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
 

Prevalence of Retinopathy of Prematurity

  • 1. The Prevalence Of Retinopathy Of Prematurity And Relationship With Various Factors Among Infants Admitted In SNCU ,RIMS RANCHI Contributing To Screening Programmes By - Dr. Abhishek Kumar Sinha Junior Resident,R.I.M.S Ranchi
  • 2. Introduction ❖ Retinopathy of prematurity (ROP) is a proliferative retinopathy which is the preventable common cause of the blindness in preterm infants. Detection and treatment of the ROP have become more important because the progression of the disease is very quick. It has several risk factors but the most important risk factors are low gestational age (GA) and low birth weight (BW) [1]. A lot of screening guidelines have been based on these factors to identify infants needing examination. ❖ The incidence of the ROP is different in countries. In developed countries, ROP-associated blindness incidence has been reported to be lower than 10% of extremely preterm born children but in middle-income countries, the incidence is greater than 40% . ❖ In this retrospective study, we analyzed the incidence of ROP. We aimed to contribute to screening programmes.
  • 3. Subjects and Methods ❖ Approval was obtained from the local ethics committee for the study. The study conformed to the tenets of the Declaration of Helsinki. ❖ In this retrospective study,182 premature infants who were born with GA ≤ 37 weeks at our hospital were examined. ❖ Exclusion criteria were lethal congenital anomalies, death before examination, death or loss to follow up before complete retinal vascularisation has developed and incomplete screening procedure.
  • 4. ❖ ROP was classified according to the international classification of ROP and screening procedure was designed in accordance with suggestions of the American Academy of Pediatrics, American Academy of Ophthalmology and American Association for Pediatric Ophthalmology and Strabismus. ❖ The diagnosis of severe ROP is defined as threshold and type 1 pre- threshold ROP. The Early Treatment for Retinopathy of Prematurity (ETROP) study results recommended treating ROP with laser photocoagulation. In zone II or III cases, we preferred laser treatment. In zone I or posterior zone II cases, we prefer anti-VEGF.
  • 5. ❖ Infants were classified into 4 groups according to GA; < 28 week, 28 - 31 weeks, 32 - 34 weeks, 35 - 37 weeks. Infants also classified into 8 groups according to the BW; ≤ 750g, 751 - 999g, 1000 - 1249g, 1250 - 1499g, 1500 - 1749g, 1750 - 1999g, 2000 - 2499g, ≥ 2500g. ❖ Data analysis was conducted using SPSS V.20.0 (SPSS Inc., Chicago, IL). Chi-square test was used to analyze qualitative variables. A difference with p < 0.05 was considered significant.
  • 6. Results ❖ During the study period, a total number of 182 preterm infants [105 female (58%) & 77 male (42%)] with ≤ 37 week of GA were assessed. Mean GA was 31.9 ± 2.1 weeks (range: 25 - 37 weeks) and mean BW was 1575.4 ± 495.2g (range: 690 - 4050g). ❖ The overall incidence of ROP was 35% (63/182). 36 infants (58%) had stage 1, 7 infants (10%) had stage 2, 14 infants (22%) had stage 3, 2 infants (0.03%) had stage 4 and 5 of the disease and 4 infants (0.07%) had aggressive posterior retinopathy of prematurity (APROP). Mean GA who had any stage of the disease was 30.1 ± 2.1 weeks (range: 24 - 35.9 weeks) and mean BW was 1263.6 ± 390.2g (range: 690 - 3190g).
  • 7. ❖ The incidence of ROP in female and male infants were 39% (40/105), 29% (22/77), respectively. There was no significant difference between genders (p = 0.065). ❖ The incidence of ROP in GA with < 28 week was 100%, 28 - 31 weeks was 63%, 32 - 34 weeks was 15%, 35 - 37 weeks was 13%. The incidence rate of the disease was increased with the decrease in the GA (p < 0.001)
  • 8. Variables ROP Number(%) No ROP Number (%) P Gender Female Male 40(39%) 22(29%) 64(61%) 55(71%) 0.065 Gestational age (weeks) < 28 weeks 28 - 31 weeks 32 - 34 weeks 35 - 37 weeks 10(100%) 36(63%) 11(15%) 5(13%) 0(0%) 21(37%) 67(85%) 32(87%) <0.001 Birth weight (g) < 750 g 750 - 999g 1000 - 1249g 1250 - 1499g 1500 - 1749g 1750 - 1999g 2000 - 2499g > 2500g 1(100%) 10(91) 10(71%) 11(44%) 13(37%) 9(29%) 4(11%) 5(16%) 0(0) 1(9%) 5(29%) 13(56%) 23(63%) 22(71%) 33(89%) 22(84%) <0.001
  • 9. Variables Stage 1 Stage 2 Stage 3 Stage 4a Stage 4b Stage 5 APROP P Gender Female Male 22(56%) 12(62%) 5(12%) 2(9%) 9(22%) 5(21%) 1(2%) 0(0%) 0(0%) 1(0.5%) 0(0%) 0(0%) 3(8%) 2(1%) 0.940 Gestational age (weeks) < 28 weeks 28 - 31 weeks 32 - 34 weeks 35 - 37 weeks 3(30%) 21(58%) 7(69%) 3(60%) 2(20%) 4(11%) 0(0%) 1(20%) 3(30%) 7(20%) 3(23%) 1(20%) 0(0%) 1(3%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 2(20%) 3(8%) 1(8%) 0(0%) 0.018 Birth weight (g) < 750 g 750 - 999g 1000 - 1249g 1250 - 1499g 1500 - 1749g 1750 - 1999g 2000 - 2499g > 2500g 0(0%) 4(40%) 5(50%) 6(63) 5(54%) 10(76%) 2(67%) 2(50%) 0(0%) 1(1%) 2(20) 4(13%) 0(0%) 0(0%) 0(0%) 1(25%) 2(67%) 3(30%) 2(20) 2(21%) 0(0%) 0(0%) 1(33%) 1(25%) 0(0%) 1(10%) 0(0%) 0(0%) 4(36%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1(33%) 1(10%) 2(20%) 1(4%) 1(11%) 3(24%) 0(0%) 0(0%) 0.038
  • 10. Discussion ❖ ROP is a preventable blinding disease of the retina. Although diagnosing and treatment methods have been developed, ROP still threat premature infants all over the world especially in middle-income countries such as India, China,other parts of Asia, Eastern Europa, Latin America. Detection and treatment with the screening programs are very important to prevent poor vision. For screening programmes, detection of the risk factors and incidence of ROP are essential. There are several risk factors in the development of ROP but the BW and GA are considered the most important risk factors of the disease
  • 11. The Prevalence of Retinopathy of Prematurity and Relationship with Gestational Age and Birth-Weight; Contributing to Screening Programmes ❖ In our study, the overall incidence of ROP was 35% and incidence of any stage of ROP was 100% of infants with GA less than or equal to 28 weeks and 63% with GA less than or equal to 32 weeks. We also found that the incidence of ROP BW with < 750g was 100%, 750 - 999g was 91%, 1000 - 1249g was 71% and 1250 - 1499g was 44%. ❖ In our country, our city &. nearby areas are less developed-region and socioeconomic status of the population is low and these situations can explain the reason for high incidence. The other reasons may be low prenatal care, delivery care, and postnatal care standards. ❖ Screening criteria usually base on gestational age and birth weight. Several studies have been done to create criteria for ROP screening programmes. These programmes differ from one country to another country and change from time to time.
  • 12. Limitation ❖ This study has some limitations. First of all, the study population is small & the study was conducted in Ranchi only, so the results may not reflect the true incidence of ROP in India.
  • 13. Conclusions ❖ ROP is still a serious disease and its incidence is different between countries and change from time to time according to the neonatal healthcare units conditions and their developments. ❖ Screening criteria for ROP in our country must be wider than high-income countries. In India, neonatal healthcare unit conditions should be improved and national guidelines for ROP should be established.